CSLLY News and Press, CSL Ltd ADR From 04/12/23

2023-04-12 10:50:20 ET Summary CSL Limited is one of the largest global biotechnology companies globally that specializes in the research, development, and manufacturing of plasma-based therapies, vaccines, and other pharmaceutical products. The combination of long-term revenue re...

Tavneos® (avacopan) included in updated EULAR recommendations for the management of AAV Canada NewsWire Tavneos ® newly introduced in the 2022 European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of ANCA-associated vasculiti...

CSL Opens New, State-of-the-Art Vaccine Research and Development Facility in Waltham, Massachusetts PR Newswire The site will support CSL's growing R&D portfolio, accelerating the development of next-generation mRNA technology for vaccines WALTHAM, Mass. , ...

The Lancet Publishes Pivotal Phase 3 Data on CSL's First-in-Class Garadacimab for HAE PR Newswire Significant reduction in number of attacks support the potential of once-monthly garadacimab as a prophylactic therapy for patients with hereditary angioedema KING OF PRUSSI...

DUBLIN, Ireland and BRIDGEWATER, N.J. and MELBOURNE, Australia, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and CSL Seqirus today announced that the two companies have entered into an exclusive license and distribution agreement under which Amarin will license exclusive...

CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing PR Newswire Majority of patients were attack free during the entire six-month treatment period (61.5%) Study results presented for first time a...

CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb) PR Newswire Data follow the historic approval of the first gene therapy for hemophilia B, which reduces the rate of annu...

Biotech Leader CSL Again Named Among America's Best Employers by Forbes PR Newswire CSL recognized in Forbes and Statista's Best Large-sized Employer category for the fourth time since 2018. KING OF PRUSSIA, Pa. , Feb. 21, 2023 /PRNewswire/ -- Global biot...

First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission PR Newswire HEMGENIX ® underscores CSL's promise to deliver life-changing innovations that have the potential to help patients lead full lives MARBURG, Germany ...

Summary Haemonetics surpassed sell-side expectations with healthy revenue growth from Plasma and Hospital, but margin leverage was lacking due to the ongoing impact of inflation and supply chain issues. The company extended its non-exclusive supply agreement with CSL for another two yea...